Evidence for efficacy and effectiveness of the MORA Bioresonance method in smoking cessation
Poster presented during 4 European Congress for Integrative Medicine - Berlin, October 07 - 08 in 2011
Ersal Isik, Clinic Neosante, Bahariye cad. 77, 9-10 Kadikoy Istanbul, Turkey, Telephone: +90 2164 506020, e-mail: firstname.lastname@example.orgMichael Galle, Institut für Biophysikalische Medizin, Algenrodter Str. 51a, 55743 Idar-Oberstein, Germany, Telephone: +49 6781 980622, e-mail: email@example.com
IntroductionFor more than thirty years MORA bioresonance therapy (classical bioresonance therapy) is used by naturopathic practitioners all over the world for a broad range of indications (e.g. allergic diseases, rheumatic diseases). The bioresonance method is based on the discoveries of Franz Morell and Erich Rasche [1-3]. At clinical level, a lot of positive studies pertaining to several indication fields have been conducted by international work groups [e.g. 4-12]. Ultra low, coherent, low frequency (1 Hz - 10^5 Hz – range) electromagnetic oscillations are postulated as transmitters of information at a biophysical level [1-3]. However, three clinical studies [13-15] did not confirm the therapeutic effectiveness of the bioresonance method according to the author`s conclusions, so that a continuous controversial discussion is under way [e.g. 16-18]. For further clinical verification of the bioresonance method two studies with one indication, but different methodological test concepts were carried out: 1. Since 2007 until today (2011) one of the authors (EI) applies this therapy concept in his clinic for smoking cessation, and assesses its practical effectiveness at the same time . 2. Over the course of one year (2008 until 2009) Pihtili et al. 2009  verified in a clinical trial the efficacy of the MORA bioresonance method for smoking cessation as well. None of the scientists in this study had any previous experience regarding the device's use and respective method.
These studies are worldwide the first ones which verify the efficacy
The study of EI  in his clinic was carried out retrospective,
Table 1 shows the results of the study. The rate of smoking
(by a randomised, double blind placebo trial) and the effectiveness
uncontrolled and non selective (including the drop outs). It is
cessation after one week was 80.1%, after one month 62.1% and
(by practice experience) of the bioresonance method in smoking
called “non controlled study” in the following passages.
after three months 48.2% including the drop outs in the
cessation. There were no side effects identified, related to the
The study of Pihtili et al.  (Faculty of Medicine of the
calculation (see table 2). No side effects were observed.
practice of this method, like in all other published bioresonance
University of Istanbul, Department of Pulmonary Diseases) was
carried out prospective, randomised, placebo controlled and
Table 1: Rates of smoking cessation as a function of the time
double blind. It is called “placebo controlled study” in the
period after treatment in the non controlled study with 4733
Regarding the results of the placebo controlled study the
participants (number of participants, absolute and relative in
application of the active bioresonance is successful and differs
significantly and noticeably from the sham bioresonance (see table
2). Comparing the 28.6% success rate of the bioresonance
In both studies the indication was smoking. The participants
method at the end of the first year with the most effective methods
on pharmacological level (varenicline, bupropion), the most
effective medicament varenicline (see below) shows similar results
but side effects like nausea and insomnia and even partly severe
In both studies the participants were treated with the
side effects (e.g. attempted suicides), so that 2009 a warning had
bioresonance method by use of the MORA-Super device (Med-
been announced by the FDA. A lot of studies were conducted with
Tronik GmbH, Friesenheim/Baden, Germany) in a similar way.
the above mentioned medicaments. For example Oncken et al.
A smoking specific bioresonance treatment was conducted one
2006  using varenicline and bupropion documented the
time by placing smoked cigarettes in the input electrodes. 18%
following success rates after one year: 23.0% for varenicline,
of the participants in the non controlled study got a support
14.6% for bupropion and 10.3% for placebo. The three
treatment shortly after their first treatment while 16.7% received
Seven days after the bioresonance treatment the probands were
treatments differ significantly. These results are typical for many
questioned as to whether they felt that the treatment had reduced
other studies. According to the meta-analyses of Eisenberg et al.
Furthermore in both studies the anti-smoking information was
their desire to smoke. 95.8% perceived the treatment as effective,
2008  on a pharmacological level the most successful results
transferred to a liquid of 92% serum physiological with 8% ethyl
3.8% felt no effect at all and 0.4% were not contactable by phone.
alcohol as well as to a chip. The chip had to be worn below the navel for one month while the liquid should be used if the
After 3 months the uncontrolled study showed a success rate of
The effectiveness research test at the end of the first week
48.2% with the bioresonance method (see table 1). Regarding this
revealed, that the urge to smoke in the bioresonance group
time period Jorenby et al. 2006  reported 43.9% in the
Assessment, main outcome and observation time
decreased significantly compared to the placebo group,
varenicline group and 29.8% in the buproprion group. Gonzales
The probands in the non controlled study were interviewed by
respectively in the first three days (p = 0.002) and the second
et al. 2006  documented a success rate of 44.0% for
telephone regarding their smoking habit (main outcome: quitting
three days (p = 0.003). The rate of smoking without any
varenicline and 29.5% for bupropion. Also on a three month
smoking) at certain intervals (after one week, one month and
discomfort in the bioresonance group was significantly lower
observation period, the success rate of the bioresonance method is
three months). On the third day after the first treatment they were
compared to the placebo group (p = 0.003). Individuals from the
similar to the best pharmacological results.
questioned whether they needed a support treatment (still a
bioresonance group did not feel the urge to smoke in a smoking
The remarkable thing about it is that no side effects were observed
strong desire for smoking) or a second full treatment (they were
environment (p = 0.005) and overall showed no signs of irritation
in both bioresonance studies which stands in clear contrast to the
(p = 0.005). In comparison with 24.7% of the participants in the
pharmacological studies. In this context it is important to say that
In the placebo controlled study the probands were questioned
placebo group (p = 0.01), 48.0% in the bioresonance group
the above mentioned medicaments were taken daily during the
regarding their smoking habit as well (main outcome: quitting
stated, that the drops administered following the treatment session
whole observation intervals, even when the results were calculated,
smoking) at certain intervals (after one week, two weeks, one
reduced the urge to smoke. The participants of the bioresonance
whereas in the bioresonance treatment only one or maximal a few
month and one year). A questionnaire was given to them with
group which stated that the treatment was effective were
treatment sessions at the beginning were carried out and the
the objective to determine the effectiveness of the method at the
significantly higher than in the placebo group (p < 0.001). Table
probands continued their life without any medicaments which
2 shows the rates of smoking cessation. Also in this study no side
might have fairly often side effects, even partly in a serious
Information was also gathered on the participant's Fagerström
Nicotine Dependence Score, previous experience of quitting smoking and psychological treatment anamnesis.
Table 2: Rates of quitting smoking in the bioresonance and
As mentioned in the introduction, further clinical studies confirm
placebo groups (number of participants, absolute and relative in
the clinical effectiveness of bioresonance therapy in a broad range
of indications [e.g. 4-12]. Therefore these results in smoking
The non controlled study included 4733 participants (2068
cessation are no exception on a clinical research level of the
females, 2665 males). 60.8% were between the age of 30 and
bioresonance method. Even a lot of investigations with animals
50, 19.0% above 50. 44.2% had been smoking between 10
and plants give evidence for the efficacy of bioresonance method
and 20 years and 42.1% for more than 20 years. 34.4% had
smoked 11-20 and 37.0% 21-30 cigarettes daily. According to
On a physical level Korenbaum et al. 2006  showed in a
the Fagerström scale 60.1% had a high or very high addiction.
randomized and double blind trial that electronic copies of
The placebo controlled study included 95 probands (53 females,
bioactive substances, using the bioresonance method, are different
42 males) in the active bioresonance group and 94 (60 females
from placebo electronic copies in the absorption spectra in the
One month 46 (51.1%) 26 (28.6%) p = 0.002
and 34 males) in the placebo bioresonance group. The two
optical frequency range from 700 to 800 nm. Montagnier et al.
groups were statistically equal (p > 0.05) in demographic
2009  detected electromagnetic oscillations in the low
characteristics (gender, age, occupation) and smoking
frequency range (about 1000 Hz) with an experimental
anamnesis (number of cigarettes smoked daily, number of years
In every time period after treatment the rate of smoking cessation
construction which was a copy of the exogenous part of the
smoking). About 65% of the participants of the two groups were
in the bioresonance group was significantly and noticeably higher
30 to 50 years old, ca. 20% above 50. About 60% had been
than in the placebo group (see table 2).
The broad spectrum of indications and the general biological
smoking for more than 20 years, approximately 55% smoked
efficiency in connection with the ability of electromagnetic storing
11-20 and approx. 25% 21-30 cigarettes daily.
of the specific biological and clinical information points to a fundamental biophysical mechanism of effectiveness on the electromagnetic level [see 3].
17. Classen M.: Kuhmilchinduzierte Enteropathie – Diagnostik durch Bioresonanz? Pädiatrische Praxis 2007; 70(4):612-614. 18. Kleine-Tebbe J, Ballmer-Weber B, Beyer K, et al.: In-vitro-Diagnostik und molekulare Grundlagen von IgE-vermittelten Nahrungsmittelallergien. Allergo Journal 2009; 18(2): 132-146.
1. Morell F: MORA-Therapie – patienteneigene und Farblicht-schwingungen. Heidelberg, Haug 1987.
19. Isik ES: MORA bioresonance method (MORA-Therapy) to quit smoking. Clinical report 2011, Clinic Neosante, Istanbul, Turkey.
2. Herrmann E: Das MORA-Praxisbuch – Therapie mit körpereigenen Schwingungen. Haug, Heidelberg 1998.
20. Pihtili A, Cuhhadraroglu C, Kilicaslan Z, Issever H, Erkan F: The effectiveness of bioresonance method in quitting smoking. Clinical report 2009, Department of Medicine, University
3. Galle M: MORA-Bioresonanztherapie.und es funktioniert doch! Biologische Fakten -Physikalische Thesen. Wiesbaden, Pro-medicina 2002.
Istanbul, Turkey (in preparation for publication).
4. Maiko OJu, Gogoleva EF: Outpatient bioresonance treatment of gonarthrosis. Terapevticheskii Arkhiv 2000; 72 (12):50-53.
21. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist,
5 Gogoleva EF: New approaches to diagnosis and treatment of fibromyalgia in spinal osteo-chondrosis. Ter Arkh 2001; 73: 40-45.
varenicline, for smoking cessation. Arch Intern Med 2006; 166(15):1571-1577.
6. Yang J, Zhang L: 300 Behandlungsbeispiele gegen Asthma mittels BICOM-Grätes für die Kinderpatienten. Maternal and Child Health Care of China 2004; 19(9):126-127.
22. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, Gervais A, O`Loughlin J, Paradise G, Rinfret S, Pilote L: Pharmacotherapies for smoking cessation: a meta-analysis of
Two methodologically complementary studies show evidence for
7. Huang S, Sun Z, Fang Y: Klinische Behandlung vom allergischen Schnupfen und Bronchialasthma der Kinder mit dem Bioresonanztherapiegerät. Zhejiang Medical Journal 2005;
randomized controlled trials. CAMJ 2008; 179(2):135-144.
23. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR: Varenicline Phase 3 StudyGroup: Efficacy of varenicline, an alpha4beta2 nicotinic
8. Nienhaus J, Galle M: Placebokontrollierte Studie zur Wirkung einer standardisierten MORA Bioresonanztherapie auf funktionelle Magen-Darm-Beschwerden. Forschende
acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1):56-63.
significant and noticeable efficacy respectively a high practical
24. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.Varenicline, an alpha4beta2
9. Rahlfs VW, Rozehnal A: Wirksamkeit und Verträglichkeit der Bioresonanzbehandlung. Erfahrungsheilkunde 2008; 57(8):462-468.
nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1):47-55.
10. Schuller J., Galle M.: Untersuchung zur Prüfung der klinischen Wirksamkeit elektronisch abgespeicherter Zahn- und Gelenksnosoden bei Erkrankungen des Rheumatischen Formen-
25. Hutzschenreuter P Brümmer H: Die Narbe, das Keloid und die MORA-Therapie. Therapeutikon 1991; 5 (10):507-515.
effectiveness of the MORA bioresonance therapy in smoking
kreises. Forsch. Komplementärmed. 2007; 14:289-296.
26. Endler PC, Heckmann C, Lauppert E, Pongratz W, Smith CW, Senekowitsch F, Citro M: Amphibienmetamorphose und Information von Thyroxin. Speicherung durch bipolare Flüssigkeit
11. Chen T, Guo ZP, Zhang YH, Gao Y: Effect of MORA bioresonance therapy in the treatment of Henoch-Schonlein purpura and influence on serum antioxidant enzymes. Journal of
Wasser und auf technischen Datenträger; Übertragung von Information durch elektronischen Verstärker. In: P C Endler und J Schulte (Hrsg.): Homöopathie – Bioresonanztherapie: 127-
Clinical Dermatology 2010; 39(5):283-285.
12. Herrmann E, Galle M: Retrospective surgery study of the therapeutic effectiveness of MORA bioresonance therapy with conventional therapy resistant patients suffering from allergies,
27. Fedorowski A, Steciwko A, Rabczynski J: Low-frequency electromagnetic stimulation may lead to regression of Morris Hepatoma in Buffalo rats. The Journal of Alternative and
pain and infection diseases. Accepted for publication in June 2011 in European Journal of Integrative Medicine.
Complementary Medicine 2004: 10(2):251-260.
13. Kofler H, Ulmer H, Mechtler E, Falk M, Fritsch PO: Bioresonanz bei Pollinose – eine vergleichende Untersuchung zur diagnostischen und therapeutischen Wertigkeit. Allergologie
28. Thomas Y, Kahhak L, Aissa J: The physical nature of the biological signal, a puzzling phenomenon: the critical contribution of Jaques Benveniste. In: G.H. Pollack, I.L. Cameron, D.N.
Wheatley (ed.): Water and the cell: 325-340, Springer, Dordrecht, Netherlands 2006.
14. Schöni MH, Nikolaizik WH, Schöni-Affolter F: Efficacy Trial of Bioresonance in Children with atopic dermatitis. International Archives of Allergy and Immunology 1997; 112: 238-246.
29. Korenbaum VI, Chernysheva TN, Apukhtina TP, Sovetnikova LN: Absorption spectra of electronic-homoeopathic copies of homoeopathic nosodes and placebo have essential
15. Wille A: Bioresonanztherapie (biophysikalische Informationstherapie) bei stotternden Kindern. Forschende Komplementärmedizin 1999; 6, Suppl. 1:50-52.
differences. Forschende Komplementärmedizin 2006; 13:294-297.
16. Wüthrich B, Frei PC, Bircher A, et al.: Bioresonanz – diagnostischer und therapeutischer Unsinn. Schweizerische Ärztezeitung 2006; 87:50-54.
30. Montagnier L, Aissa J, Ferris S, Montagnier J-J, Lavallee C: Electromagnetic signals are produced by aqueous nanostructures derived from bacterial DNA sequences. Interdisciplinary Sciences: Computational Life Sciences 2009; 1:81-90.
EryDel announces US IND approval for EryDex Urbino, Italy – April 29 - EryDel SpA (www.erydel.com), a Drug Delivery Company specialized in the development of drugs and diagnostics delivered through red blood cells (RBCs), announced today that it has received approval to start its first study in the US. The Investigational New Drug (IND) Application for EryDex (Dexamethasone Sodium Phosphate
R E S E A R C H A N D D E V E LO P M E NT Where Is the New Science most new science in developed rather thandeveloping economies for reasons that may not in Corporate R&D? always characterize the U.S. situation. Jerry Thursby and Marie Thursby* The idea that the United States domi- or currently planned R&D facility both views of corporate R&D. For example,outside and inside